Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial
Posted innews OB/GYN & Women’s Health Oncology

Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial

The I-SPY2 trial shows that combining PD-1 and LAG-3 inhibitors with neoadjuvant chemotherapy significantly improves pathologic complete response rates in early-stage high-risk ERBB2-negative breast cancer, especially in patients with a positive immune signature.
Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry
Posted inAllergy & Immunology Hematology-Oncology news

Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for improved diagnostic and management strategies.
Determinants of One-Year Success in Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study
Posted inDiabetes & Endocrinology news Ophthalmology

Determinants of One-Year Success in Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study

This article examines factors influencing the one-year success rate of DMEK in treating corneal endothelial dysfunction, highlighting the impact of operative complications and donor-recipient variables based on findings from the Diabetes Endothelial Keratoplasty Study (DEKS).